First Time Loading...

Venus Remedies Ltd
NSE:VENUSREM

Watchlist Manager
Venus Remedies Ltd Logo
Venus Remedies Ltd
NSE:VENUSREM
Watchlist
Price: 301.85 INR 1.58% Market Closed
Updated: May 28, 2024
Section:
 

Relative Value

The Relative Value of one VENUSREM stock under the Base Case scenario is 593.18 INR. Compared to the current market price of 301.85 INR, Venus Remedies Ltd is Undervalued by 49%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VENUSREM Relative Value
Base Case
593.18 INR
Undervaluation 49%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.7
P/S
P/S
Price to Sales
0.7
vs History
20
vs Industry
78
Median 3Y
0.7
Median 5Y
0.5
Industry
2.4
Forward
0.6
More Details
13.9
P/E
P/E
Price to Earnings
13.9
vs History
28
vs Industry
32
Median 3Y
10
Median 5Y
8.2
Industry
22.8
Forward
11.8
More Details
26.9
P/OCF
P/OCF
Price to OCF
26.9
vs History
9
vs Industry
17
Median 3Y
8.1
Median 5Y
5.8
Industry
17
More Details
66.1
P/FCFE
P/FCFE
Price to FCFE
66.1
vs History
9
vs Industry
9
Median 3Y
15.8
Median 5Y
9.4
Industry
23.2
More Details
0.9
P/B
P/B
Price to Book Value
0.9
vs History
30
vs Industry
65
Median 3Y
0.8
Median 5Y
0.6
Industry
2.1
More Details
0.7
EV/S
EV/S
Enterprise Value to Sales
0.7
vs History
26
vs Industry
80
Median 3Y
0.6
Median 5Y
0.6
Industry
2.6
Forward
0.6
More Details
1.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.5
vs History
31
vs Industry
76
Median 3Y
1.7
Median 5Y
1.4
Industry
5.1
More Details
5.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.6
vs History
36
vs Industry
44
Median 3Y
5.5
Median 5Y
5.1
Industry
13.5
Forward
5.4
More Details
10.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
10.2
vs History
63
vs Industry
37
Median 3Y
11.8
Median 5Y
11.6
Industry
16.9
More Details
24.6
EV/OCF
EV/OCF
Enterprise Value to OCF
24.6
vs History
9
vs Industry
19
Median 3Y
7.5
Median 5Y
5.3
Industry
15.8
More Details
54.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
54.9
vs History
9
vs Industry
9
Median 3Y
10.5
Median 5Y
6.8
Industry
17.7
More Details
0.7
EV/IC
EV/IC
Enterprise Value to IC
0.7
vs History
31
vs Industry
68
Median 3Y
0.7
Median 5Y
0.6
Industry
1.9
More Details

Multiples Across Competitors

VENUSREM Competitors Multiples
Venus Remedies Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Venus Remedies Ltd
NSE:VENUSREM
4B INR 0.7 13.9 5.6 10.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
763.8B USD 21.2 124 60.9 69.3
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 16.7 45.7 34.1 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
347.4B USD 4.1 9 11.1 14.5
US
Merck & Co Inc
NYSE:MRK
319.3B USD 5.2 138.3 34.6 56.4
UK
AstraZeneca PLC
LSE:AZN
186.5B GBP 5 37.5 174.5 278.3
CH
Roche Holding AG
SIX:ROG
182.4B CHF 3.1 15.9 9 10.7
CH
Novartis AG
SIX:NOVN
178.3B CHF 3.3 11.1 8.5 12.4
US
Pfizer Inc
NYSE:PFE
159.5B USD 2.9 -516.2 12.6 20.3
P/E Multiple
Earnings Growth
IN
Venus Remedies Ltd
NSE:VENUSREM
Average P/E: 49.4
13.9
91%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
124
364%
DK
Novo Nordisk A/S
CSE:NOVO B
45.7
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9
-21%
US
Merck & Co Inc
NYSE:MRK
138.3
7 598%
UK
AstraZeneca PLC
LSE:AZN
37.5
175%
CH
Roche Holding AG
SIX:ROG
15.9
28%
CH
Novartis AG
SIX:NOVN
11.1
17%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -516.2
683%

See Also

Summary
VENUSREM intrinsic value, competitors valuation, and company profile.
DCF Valuation
VENUSREM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VENUSREM stock valuation using valuation multiples.
Wall Street Estimates
VENUSREM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VENUSREM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 141,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.